Evicenter
MarkdownMedical informationP&T meetings
Lonimecgene renparvovec (TSHA-102)

Rett syndrome

Launch
Not announced
Last updated
199 sources

Clinical evidence

REVEAL part A

65 evidence topics · 23 sources

Objective
Location and study date
Adolescent and adult trial (NCT05606614): registry dates
MilestoneRegistry record
Study start (actual)“2023-03-06”
Primary completion (estimated)“2031-06”
Study completion (estimated)“2031-06”
Last update posted“2026-07-07”
Adolescent and adult trial (NCT05606614): registered sites for Parts A and B
Pediatric trial (NCT06152237): registry dates
MilestoneRegistry record
Study start (actual)“2023-12-12”
Primary completion (estimated)“2028-11-02”
Study completion (estimated)“2031-11-02”
Last update posted“2025-10-15”
Study design
Pediatric trial (NCT06152237): registered design elements
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Individual participants: age at dosing, baseline CGI-S, and follow-up
Cohort and participantAge at dosing (years)Baseline CGI-S scorePost-treatment follow-up (months)
Low dose, participant 1“20”“6”“30”
Low dose, participant 2“21”“4”“30”
Low dose, participant 3“6”“5”“24”
Low dose, participant 4“7”“4”“24”
High dose, participant 1“15”“5”“18”
High dose, participant 2“21”“5”“18”
High dose, participant 3“8”“5”“18”
High dose, participant 4“15”“5”“12”
High dose, participant 5“16”“5”“12”
High dose, participant 6“6”“4”“12”
High dose, participant 7“7”“6”“12”
High dose, participant 8“6”“5”“12”
Efficacy results
Responses at 6, 12, and at least 18 months (May 2026 data cutoff)
Endpoint6 months (N=12)12 months (N=12)18 months or more (N=7)
Participants who gained or regained at least one developmental milestone“83%”“100%”“100%”
Average functional gains per participant“22”“23”“26”
R-MBA mean score change versus natural history“-11.0 P = 0.0011”“-10.3 P = 0.0002”“-11.0 P = 0.0046”
Participants with CGI-I score of 3 or less at multiple post-treatment assessments“100%”“100%”“100%”
Participants with CGI-S total score improvement“25%”“25%”“57%”
Health-related quality of life and patient-reported outcomes
Health-related quality of life instrument results

No evidence found.

Safety results
Treatment-emergent adverse events across the 12 participants (May 2026 data cutoff)
Event categoryLow dose, participantsLow dose, eventsHigh dose, participantsHigh dose, eventsTotal, participantsTotal, events
TEAE related to TSHA-102“4”“17”“5”“20”“9”“37”
Serious TEAE unrelated to TSHA-102“3”“9”“4”“8”“7”“17”
Serious TEAE related to TSHA-102“0”“0”“0”“0”“0”“0”
Study limitations
Summary
  • Pooled sample: REVEAL Part A combines two separately registered phase 1/2 dose-escalation trials, NCT05606614 Part A (females aged 12 to <22 years) and NCT06152237 (females aged 5 to 8 years), into one analysis of 12 participants, 4 at the low dose and 8 at the high dose. Comparisons between doses rest on groups of 4 and 8 participants, and comparisons between age groups on 6 pediatric and 6 adolescent or adult participants.
  • No concurrent control: Part A of both trials is open label, and the 2026 poster describes each participant as their own control. Efficacy is judged against each participant's baseline and against external data from the Rett syndrome Natural History Study. The R-MBA comparison draws on natural history samples of 75 participants at 6 months and 196 at 12 months, with MBA scores converted to R-MBA.
  • Efficacy endpoints outside the registered Part A outcomes: the registered primary outcome of Part A in both trials is the proportion or incidence of participants with treatment-emergent adverse events and serious adverse events. Developmental milestone gain or regain, the primary evidence of efficacy in the 2026 poster, is registered as the primary outcome of Part B, and the poster describes evaluation criteria applied to available video-evidenced milestone data. The counts of additional skills derived from the MSEL-A, ORCA, and R-MBA come from a supplemental analysis, with ORCA data for 8 and MSEL-A data for 7 of the 12 participants; an earlier company announcement reported 165 additional skills or improvements across 10 participants from the same scales.
  • Masking: the pediatric trial is registered with no masking. In the adolescent and adult trial, only the central raters of milestone videos are masked, and only to the timing of each video. The R-MBA is a clinician-reported evaluation and ORCA a caregiver-reported evaluation, collected in open-label trials.
  • Follow-up: all 12 participants had at least 12 months of follow-up (range 12 to 30 months), and results at 18 months or more rest on 7 participants.
  • Concomitant immunosuppression: prednisolone and sirolimus begin 7 days before dosing and are tapered over the following months. In the company's 2024 first-cohort data presentation, the most common event, vomiting, was described as a known risk of sirolimus, and eight nonserious events were attributed to immunosuppression.
  • Heterogeneous population: participants were 6 to 21 years of age at dosing, had baseline CGI-S scores of 4 to 6, and carried varied MECP2 mutations; the pediatric trial was opened to stage three Rett syndrome and the adolescent and adult trial to stage four Rett syndrome.
  • Sponsor reporting: all results come from Taysha press releases, SEC filings, presentations, and congress posters, and the 2025 poster states that its data came from the electronic data capture system and were subject to change.
  • Inconsistencies between documents: the low dose was stated as 5x10^14 vg in June 2023 and as 5.7x10^14 vg in the registry and the third quarter 2026 Form 10-Q. The third quarter 2026 Form 10-Q describes both trials as randomized and NCT06152237 lists randomized allocation, while NCT05606614 lists non-randomized allocation, the 2023 pediatric design poster describes Part A as a single-arm dose escalation, and the 2024 first-cohort presentation plans randomization in Part B. The 2024 announcements planned at least 3 participants per dose in the pediatric trial and 3 high-dose participants in the adolescent and adult trial; NCT05606614 enrolled 2 low-dose and 4 high-dose participants, and the 12 Part A participants comprised 4 low-dose and 8 high-dose participants.